Details for New Drug Application (NDA): 077513
✉ Email this page to a colleague
NDA 077513 describes RAMIPRIL, which is a drug marketed by Accord Hlthcare, Actavis Elizabeth, Aurobindo Pharma Ltd, Chartwell Molecular, Chartwell Rx, Cipla, Corepharma, Dr Reddys Labs Ltd, Hikma, Lupin, Ranbaxy Labs Ltd, Teva Pharms, Watson Labs, Zydus Pharms Usa, Apotex, Natco Pharma, and Zydus Pharms Usa Inc, and is included in seventeen NDAs. It is available from eighteen suppliers. Additional details are available on the RAMIPRIL profile page.
The generic ingredient in RAMIPRIL is ramipril. There are nineteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the ramipril profile page.
The generic ingredient in RAMIPRIL is ramipril. There are nineteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the ramipril profile page.
Summary for 077513
| Tradename: | RAMIPRIL |
| Applicant: | Actavis Elizabeth |
| Ingredient: | ramipril |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 077513
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 1.25MG | ||||
| Approval Date: | Jun 18, 2008 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 2.5MG | ||||
| Approval Date: | Jun 18, 2008 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 5MG | ||||
| Approval Date: | Jun 18, 2008 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
